Muin J Khoury

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9579174/publications.pdf

Version: 2024-02-01

66343 46799 8,469 120 42 89 citations h-index g-index papers 127 127 127 12651 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Increasing value and reducing waste in research design, conduct, and analysis. Lancet, The, 2014, 383, 166-175.	13.7	1,186
2	The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?. Genetics in Medicine, 2007, 9, 665-674.	2.4	618
3	Deploying whole genome sequencing in clinical practice and public health: Meeting the challenge one bin at a time. Genetics in Medicine, 2011, 13, 499-504.	2.4	451
4	Precision Public Health for the Era of Precision Medicine. American Journal of Preventive Medicine, 2016, 50, 398-401.	3.0	398
5	A navigator for human genome epidemiology. Nature Genetics, 2008, 40, 124-125.	21.4	365
6	Big data meets public health. Science, 2014, 346, 1054-1055.	12.6	298
7	Charting a future for epidemiologic training. Annals of Epidemiology, 2015, 25, 458-465.	1.9	280
8	Convergence of Implementation Science, Precision Medicine, and the Learning Health Care System. JAMA - Journal of the American Medical Association, 2016, 315, 1941.	7.4	258
9	Improving Validation Practices in "Omics―Research. Science, 2011, 334, 1230-1232.	12.6	215
10	The Emergence of Translational Epidemiology: From Scientific Discovery to Population Health Impact. American Journal of Epidemiology, 2010, 172, 517-524.	3.4	209
11	The Scientific Foundation for Personal Genomics: Recommendations from a National Institutes of Health–Centers for Disease Control and Prevention Multidisciplinary Workshop. Genetics in Medicine, 2009, 11, 559-567.	2.4	207
12	Will Precision Medicine Improve Population Health?. JAMA - Journal of the American Medical Association, 2016, 316, 1357.	7.4	157
13	Do We Need Genomic Research for the Prevention of Common Diseases with Environmental Causes?. American Journal of Epidemiology, 2005, 161, 799-805.	3.4	141
14	Cascade Screening for Familial Hypercholesterolemia and the Use of Genetic Testing. JAMA - Journal of the American Medical Association, 2017, 318, 381.	7.4	138
15	Invited Commentary: From Genome-Wide Association Studies to Gene-Environment-Wide Interaction StudiesChallenges and Opportunities. American Journal of Epidemiology, 2008, 169, 227-230.	3.4	133
16	From Public Health Emergency to Public Health Service: The Implications of Evolving Criteria for Newborn Screening Panels. Pediatrics, 2006, 117, 923-929.	2.1	112
17	A Population Approach to Precision Medicine. American Journal of Preventive Medicine, 2012, 42, 639-645.	3.0	111
18	From public health genomics to precision public health: a 20-year journey. Genetics in Medicine, 2018, 20, 574-582.	2.4	109

#	Article	IF	CITATIONS
19	On the synthesis and interpretation of consistent but weak gene-disease associations in the era of genome-wide association studies. International Journal of Epidemiology, 2007, 36, 439-445.	1.9	107
20	The Evidence Dilemma In Genomic Medicine. Health Affairs, 2008, 27, 1600-1611.	5.2	105
21	Transforming Epidemiology for 21st Century Medicine and Public Health. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 508-516.	2.5	104
22	The current state of implementation science in genomic medicine: opportunities for improvement. Genetics in Medicine, 2017, 19, 858-863.	2.4	102
23	Prevalence and Predictors of Cholesterol Screening, Awareness, and Statin Treatment Among US Adults With Familial Hypercholesterolemia or Other Forms of Severe Dyslipidemia (1999–2014). Circulation, 2018, 137, 2218-2230.	1.6	100
24	The emergence of epidemiology in the genomics age. International Journal of Epidemiology, 2004, 33, 936-944.	1.9	84
25	Assessing Value in Biomedical Research. JAMA - Journal of the American Medical Association, 2014, 312, 483.	7.4	82
26	A Public Health Perspective on a National Precision Medicine Cohort. JAMA - Journal of the American Medical Association, 2015, 313, 2117.	7.4	82
27	Current Priorities for Public Health Practice in Addressing the Role of Human Genomics in Improving Population Health. American Journal of Preventive Medicine, 2011, 40, 486-493.	3.0	71
28	Descriptive epidemiology of small intestinal atresia, Atlanta, Georgia. Teratology, 1993, 48, 441-450.	1.6	60
29	Will Genomics Widen or Help Heal the Schism Between Medicine and Public Health?. American Journal of Preventive Medicine, 2007, 33, 310-317.	3.0	57
30	The Genomic Applications in Practice and Prevention Network. Genetics in Medicine, 2009, 11, 488-494.	2.4	57
31	A systematic review of cancer GWAS and candidate gene meta-analyses reveals limited overlap but similar effect sizes. European Journal of Human Genetics, 2014, 22, 402-408.	2.8	54
32	Precision Public Health as a Key Tool in the COVID-19 Response. JAMA - Journal of the American Medical Association, 2020, 324, 933.	7.4	54
33	Comparative effectiveness research and genomic medicine: An evolving partnership for 21st century medicine. Genetics in Medicine, 2009, 11, 707-711.	2.4	53
34	Beyond Base Pairs to Bedside: A Population Perspective on How Genomics Can Improve Health. American Journal of Public Health, 2012, 102, 34-37.	2.7	51
35	Reducing the burden of disease and death from familial hypercholesterolemia: A call to action. American Heart Journal, 2014, 168, 807-811.	2.7	51
36	Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. Genetics in Medicine, 2017, 19, 1-11.	2.4	49

#	Article	IF	CITATIONS
37	GAPscreener: An automatic tool for screening human genetic association literature in PubMed using the support vector machine technique. BMC Bioinformatics, 2008, 9, 205.	2.6	45
38	How can polygenic inheritance be used in population screening for common diseases? Genetics in Medicine, 2013, 15, 437-443.	2.4	45
39	Population Sciences, Translational Research, and the Opportunities and Challenges for Genomics to Reduce the Burden of Cancer in the 21st Century. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2105-2114.	2.5	44
40	Multilevel Research and the Challenges of Implementing Genomic Medicine. Journal of the National Cancer Institute Monographs, 2012, 2012, 112-120.	2.1	43
41	"Drivers―of Translational Cancer Epidemiology in the 21st Century: Needs and Opportunities. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 181-188.	2.5	43
42	Leveraging Implementation Science to Address Health Disparities in Genomic Medicine: Examples from the Field. Ethnicity and Disease, 2019, 29, 187-192.	2.3	43
43	Trends in utilization and costs of BRCA testing among women aged 18–64 years in the United States, 2003–2014. Genetics in Medicine, 2018, 20, 428-434.	2.4	42
44	Communication of cancer-related genetic and genomic information: A landscape analysis of reviews. Translational Behavioral Medicine, 2018, 8, 59-70.	2.4	41
45	A collaborative translational research framework for evaluating and implementing the appropriate use of human genome sequencing to improve health. PLoS Medicine, 2018, 15, e1002631.	8.4	40
46	Family History and Personal Genomics As Tools for Improving Health in an Era of Evidence-Based Medicine. American Journal of Preventive Medicine, 2010, 39, 184-188.	3.0	39
47	SEER Cancer Registry Biospecimen Research: Yesterday and Tomorrow. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2681-2687.	2.5	39
48	Health equity in the implementation of genomics and precision medicine: A public health imperative. Genetics in Medicine, 2022, 24, 1630-1639.	2.4	38
49	Emerging Concepts in Precision Medicine and Cardiovascular Diseases in Racial and Ethnic Minority Populations. Circulation Research, 2019, 125, 7-13.	4.5	37
50	<i>BRCA</i> Genetic Testing and Receipt of Preventive Interventions Among Women Aged 18–64 Years with Employer-Sponsored Health Insurance in Nonmetropolitan and Metropolitan Areas — United States, 2009–2014. MMWR Surveillance Summaries, 2017, 66, 1-11.	34.6	33
51	Comparative epidemiology of selected midline congenital abnormalities. Genetic Epidemiology, 1994, 11, 141-154.	1.3	32
52	From genomic medicine to precision medicine: highlights of 2015. Genome Medicine, 2016, 8, 12.	8.2	32
53	Utilization of genetic tests: analysis of gene-specific billing in Medicare claims data. Genetics in Medicine, 2017, 19, 890-899.	2.4	31
54	Evaluating the role of public health in implementation of genomics-related recommendations: a case study of hereditary cancers using the CDC Science Impact Framework. Genetics in Medicine, 2019, 21, 28-37.	2.4	31

#	Article	IF	Citations
55	DNA-Based Population Screening. JAMA - Journal of the American Medical Association, 2020, 323, 307.	7.4	31
56	Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research. Genetics in Medicine, 2013, 15, 630-638.	2.4	30
57	Translational research is a key to nongeneticist physicians' genomics education. Genetics in Medicine, 2014, 16, 871-873.	2.4	30
58	A Proposed Approach for Implementing Genomics-Based Screening Programs for Healthy Adults. NAM Perspectives, 0, , .	2.9	30
59	Evidence-based medicine and big genomic data. Human Molecular Genetics, 2018, 27, R2-R7.	2.9	29
60	Horizon scanning for translational genomic research beyond bench to bedside. Genetics in Medicine, 2014, 16, 535-538.	2.4	28
61	Cancer communication research in the era of genomics and precision medicine: a scoping review. Genetics in Medicine, 2019, 21, 1691-1698.	2.4	27
62	Knowledge integration at the center of genomic medicine. Genetics in Medicine, 2012, 14, 643-647.	2.4	26
63	Are randomized trials obsolete or more important than ever in the genomic era?. Genome Medicine, 2013, 5, 32.	8.2	26
64	No Shortcuts on the Long Road to Evidence-Based Genomic Medicine. JAMA - Journal of the American Medical Association, 2017, 318, 27.	7.4	26
65	Beyond Public Health Genomics: Can Big Data and Predictive Analytics Deliver Precision Public Health?. Public Health Genomics, 2018, 21, 244-250.	1.0	26
66	The intersection of genomics and big data with public health: Opportunities for precision public health. PLoS Medicine, 2020, 17, e1003373.	8.4	26
67	Genomics in Public Health: Perspective from the Office of Public Health Genomics at the Centers for Disease Control and Prevention (CDC). Healthcare (Switzerland), 2015, 3, 830-837.	2.0	25
68	Precision Health Analytics With Predictive Analytics and Implementation Research. Journal of the American College of Cardiology, 2020, 76, 306-320.	2.8	25
69	Perspective: The Clinical Use of Polygenic Risk Scores: Race, Ethnicity, and Health Disparities. Ethnicity and Disease, 2019, 29, 513-516.	2.3	24
70	Public Health Genomics Approach to Type 2 Diabetes. Diabetes, 2008, 57, 2911-2914.	0.6	22
71	Genetic epidemiology with a Capital E, ten years after. Genetic Epidemiology, 2011, 35, 845-852.	1.3	22
72	Can targeted genetic testing offer useful health information to adoptees?. Genetics in Medicine, 2015, 17, 533-535.	2.4	21

#	Article	IF	Citations
73	A proposed approach to accelerate evidence generation for genomic-based technologies in the context of a learning health system. Genetics in Medicine, 2018, 20, 390-396.	2.4	20
74	The impact of genomics on precision public health: beyond the pandemic. Genome Medicine, 2021, 13, 67.	8.2	20
75	Public health genomics: The end of the beginning. Genetics in Medicine, 2011, 13, 206-209.	2.4	19
76	A knowledge base for tracking the impact of genomics on population health. Genetics in Medicine, 2016, 18, 1312-1314.	2.4	17
77	The contribution of family history to the burden of diagnosed diabetes, undiagnosed diabetes, and prediabetes in the United States: analysis of the National Health and Nutrition Examination Survey, 2009–2014. Genetics in Medicine, 2018, 20, 1159-1166.	2.4	17
78	Evidence synthesis and guideline development in genomic medicine: current status and future prospects. Genetics in Medicine, 2015, 17, 63-67.	2.4	16
79	The need for a next-generation public health response to rare diseases. Genetics in Medicine, 2017, 19, 489-490.	2.4	16
80	Clinical utility of genetic and genomic services: context matters. Genetics in Medicine, 2016, 18, 672-674.	2.4	15
81	Commentary: Epidemiology and the Continuum from Genetic Research to Genetic Testing. American Journal of Epidemiology, 2002, 156, 297-299.	3.4	14
82	Opportunities for Translational Epidemiology: The Important Role of Observational Studies to Advance Precision Oncology. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 484-489.	2.5	13
83	Is there a need for PGxceptionalism?. Genetics in Medicine, 2011, 13, 866-867.	2.4	13
84	From genes to public health: are we ready for DNA-based population screening?. Genetics in Medicine, 2021, 23, 996-998.	2.4	12
85	Current Social Media Conversations about Genetics and Genomics in Health: A Twitter-Based Analysis. Public Health Genomics, 2018, 21, 93-99.	1.0	11
86	Ten years of Genome Medicine. Genome Medicine, 2019, 11, 7.	8.2	11
87	Addressing the routine failure to clinically identify monogenic cases of common disease. Genome Medicine, 2022, 14, .	8.2	11
88	Frontiers in Cancer Epidemiology: A Challenge to the Research Community from the Epidemiology and Genomics Research Program at the National Cancer Institute: Figure 1 Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 999-1001.	2.5	10
89	Communication About Hereditary Cancers on Social Media: A Content Analysis of Tweets About Hereditary Breast and Ovarian Cancer and Lynch Syndrome. Journal of Cancer Education, 2020, 35, 131-137.	1.3	9
90	Why Hasn't Genomic Testing Changed the Landscape in Clinical Oncology?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , e52-e55.	3.8	9

#	Article	IF	CITATIONS
91	Why should genomic medicine become more evidence-based?. Genomic Medicine, 2007, $1,91-93$.	0.3	8
92	Cancer Screening and Genetics: A Tale of Two Paradigms. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 909-916.	2.5	8
93	An overview of recommendations and translational milestones for genomic tests in cancer. Genetics in Medicine, 2015, 17, 431-440.	2.4	8
94	Evolution of the "Drivers" of Translational Cancer Epidemiology: Analysis of Funded Grants and the Literature. American Journal of Epidemiology, 2015, 181, 451-458.	3.4	8
95	Family History–Wide Association Study to Identify Clinical and Environmental Risk Factors for Common Chronic Diseases. American Journal of Epidemiology, 2019, 188, 1563-1568.	3.4	8
96	Redundant meta-analyses are common in genetic epidemiology. Journal of Clinical Epidemiology, 2020, 127, 40-48.	5 . 0	8
97	A scoping review of social and behavioral science research to translate genomic discoveries into population health impact. Translational Behavioral Medicine, 2021, 11, 901-911.	2.4	8
98	2012 highlights in translational 'omics. Genome Medicine, 2013, 5, 10.	8.2	7
99	Scientific reporting is suboptimal for aspects that characterize genetic risk prediction studies: a review of published articles based on the Genetic RIsk Prediction Studies statement. Journal of Clinical Epidemiology, 2014, 67, 487-499.	5.0	7
100	Implementation of the 21-gene recurrence score test in the United States in 2011. Genetics in Medicine, 2016, 18, 982-990.	2.4	6
101	Precision Medicine vs Preventive Medicine. JAMA - Journal of the American Medical Association, 2019, 321, 406.	7.4	6
102	Predictive Analytics: Helping Guide the Implementation Research Agenda at the National Heart, Lung, and Blood Institute. Global Heart, 2019, 14, 75.	2.3	6
103	Predicting intrauterine growth reterdation in sibships while considering maternal and infant covariates. Genetic Epidemiology, 1989, 6, 525-535.	1.3	5
104	Khoury et al. Respond to "The Epicenter of Translational Science": Crossing All the T's. American Journal of Epidemiology, 2010, 172, 528-529.	3.4	4
105	Harnessing the Power of Collaboration and Training Within Clinical Data Science to Generate Realâ€World Evidence in the Era of Precision Oncology. Clinical Pharmacology and Therapeutics, 2019, 106, 60-66.	4.7	4
106	Using deep learning to identify translational research in genomic medicine beyond bench to bedside. Database: the Journal of Biological Databases and Curation, 2019, 2019, .	3.0	4
107	HLBS-PopOmics: an online knowledge base to accelerate dissemination and implementation of research advances in population genomics to reduce the burden of heart, lung, blood, and sleep disorders. Genetics in Medicine, 2019, 21, 519-524.	2.4	4
108	Utility before business. Genetics in Medicine, 2014, 16, 869-870.	2.4	3

#	Article	IF	CITATIONS
109	Challenges and Opportunities for Communication about the Role of Genomics in Public Health. Public Health Genomics, 2021, 24, 67-74.	1.0	3
110	Evaluating Precision Medicine's Ability to Improve Population Health—Reply. JAMA - Journal of the American Medical Association, 2017, 317, 441.	7.4	2
111	Tracking human genes along the translational continuum. Npj Genomic Medicine, 2019, 4, 25.	3.8	2
112	Guidelines for submitting human genome epidemiology (HuGE) reviews toTeratology. Teratology, 2001, 63, 62-64.	1.6	1
113	The Cancer Genomics and Epidemiology Navigator: An NCI Online Tool to Enhance Cancer Epidemiology Research. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2610-2611.	2.5	1
114	The Cancer Epidemiology Descriptive Cohort Database: A Tool to Support Population-Based Interdisciplinary Research. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1392-1401.	2.5	1
115	COVID-19 GPH: tracking the contribution of genomics and precision health to the COVID-19 pandemic response. BMC Infectious Diseases, 2022, 22, 402.	2.9	1
116	The integration of genomics into paediatric and perinatal epidemiology: guidelines for submitting human genome epidemiology (HuGE) reviews. Paediatric and Perinatal Epidemiology, 2005, 19, 178-180.	1.7	0
117	Evidence Dilemma: The Authors Respond. Health Affairs, 2009, 28, 926-927.	5.2	0
118	The Authors Reply. American Journal of Epidemiology, 2015, 181, 361-361.	3.4	0
119	Epidemiology matters: peering inside the "black box―in economic evaluations of genetic testing. Genetics in Medicine, 2016, 18, 963-965.	2.4	0
120	Current status of the implementation of gene expression testing in breast cancer management in the United States Journal of Clinical Oncology, 2013, 31, 6562-6562.	1.6	0